Is it safe to use phentermine (a sympathomimetic anorectic) concomitantly with bupropion (Wellbutrin)?

Phentermine and Wellbutrin (Bupropion) Combination: Not Recommended

The FDA label explicitly states that phentermine should NOT be coadministered with other weight loss drugs, and the safety and efficacy of combination therapy with phentermine and any other drug products for weight loss have not been established 1. While bupropion is not primarily a weight loss medication, it is a component of the FDA-approved naltrexone/bupropion combination for obesity treatment, making this combination problematic.

Key Safety Concerns

FDA Position on Phentermine Combinations

The phentermine FDA label is unequivocal: "The safety and efficacy of combination therapy with phentermine and any other drug products for weight loss including prescribed drugs, over-the-counter preparations, and herbal products, or serotonergic agents such as selective serotonin reuptake inhibitors (e.g., fluoxetine, sertraline, fluvoxamine, paroxetine), have not been established. Therefore, coadministration of phentermine and these drug products is not recommended" 1.

Why This Matters for Bupropion

• Bupropion is part of an FDA-approved obesity medication (naltrexone/bupropion combination) 2, 3, placing it in the category of weight loss drugs
• Both drugs have sympathomimetic/stimulant properties that can compound cardiovascular risks
• Phentermine increases blood pressure and heart rate 2, 3, and combining it with bupropion (which also has stimulant effects) may amplify these risks
• No safety data exists for this specific combination in clinical trials

Clinical Guideline Perspective

The 2015 Endocrine Society guidelines note that phentermine is approved only as short-term monotherapy and specifically recommend against using sympathomimetic agents like phentermine in patients with cardiovascular risk factors 2. The guidelines emphasize that regulatory approval for phentermine was based on limited clinical data "without a cardiovascular outcomes study," creating uncertainty about safety across broad populations 2.

Practical Considerations

If Depression Treatment is the Priority

• If the patient needs bupropion for depression/smoking cessation, avoid adding phentermine
• Consider alternative obesity medications that don't interact: orlistat, liraglutide, or semaglutide 2, 3

If Weight Loss is the Priority

• Use phentermine alone (if no cardiovascular contraindications exist) 2, 3
• Or consider FDA-approved combinations: phentermine/topiramate ER or naltrexone/bupropion (but NOT phentermine added to bupropion separately) 2, 3

Monitoring Requirements if Combination is Unavoidable

While not recommended, if this combination is already in use:

• Monitor blood pressure and heart rate closely at every visit
• Watch for signs of excessive CNS stimulation (anxiety, insomnia, tremor, agitation)
• Screen for cardiovascular symptoms (chest pain, palpitations, dyspnea) 2, 1
• Discontinue immediately if blood pressure becomes uncontrolled or cardiovascular symptoms emerge

Common Pitfalls to Avoid

• Don't assume bupropion is "safe" because it's an antidepressant - it has stimulant properties and is part of an obesity medication
• Don't rely on "clinical experience" when FDA labels explicitly warn against combinations lacking safety data
• Don't ignore cardiovascular monitoring - both drugs can elevate blood pressure and heart rate 2, 3, 1
• Remember phentermine is only approved for short-term use ("a few weeks"), though often prescribed off-label long-term 3, 1

Bottom Line Algorithm

1. Is the patient already on bupropion for depression? → Choose a different obesity medication (orlistat, GLP-1 agonist)
2. Is weight loss the primary goal? → Use phentermine alone OR an FDA-approved combination (phentermine/topiramate or naltrexone/bupropion as a fixed combination)
3. Patient insists on both separately? → Explain FDA warnings, document discussion, and if proceeding, implement intensive cardiovascular monitoring with low threshold for discontinuation

The lack of safety data combined with explicit FDA warnings against phentermine combinations makes this a high-risk approach that should be avoided in favor of evidence-based alternatives 1.